Company Performance Metrics
- Richard Jones: Chief Executive Officer
- Andreas Bergmann: Co-Founder and Chief Scientific Officer
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options.
The Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the
vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity to treat life-threatening conditions associated with increased vascular leakage, congestion and shock.
their unique treatment approach combines the therapeutic antibody with a specific diagnostic, which uses Adrenomedullin as the biomarker to identify patients. The most important target indications are sepsis and septic shock as well as acute heart failure.
Adrenomed’s business is effectively secured by a strong IP position with granted patents in all major markets.
Adrenomed is based in Hennigsdorf near Berlin, Germany.
